Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 16/20 | 0.63 |
| ▸ | MMP13 | P45452 | 14/20 | 0.63 |
| ▸ | MMP2 | P08253 | 13/20 | 0.63 |
| ▸ | MMP3 | P08254 | 10/20 | 0.63 |
| ▸ | MMP7 | P09237 | 7/20 | 0.63 |
| ▸ | MMP9 | P14780 | 7/20 | 0.63 |
| ▸ | MMP14 | P50281 | 2/20 | 0.63 |
| ▸ | MMP8 | P22894 | 7/20 | 0.61 |
| ▸ | ADAM17 | P78536 | 9/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7219734 | 0.94 | MMP1 (0.63) | MMP1MMP13MMP2MMP3MMP7 | |
| SCHEMBL7225115 | 0.90 | MMP1 (0.61) | MMP1MMP13MMP2MMP3MMP7 | |
| SCHEMBL6162715 | 0.89 | MMP1 (0.51) | MMP1MMP13MMP2MMP3MMP7 | |
| SCHEMBL6162727 | 0.89 | MMP1 (0.51) | MMP1MMP13MMP2MMP3MMP7 | |
| SCHEMBL7219525 | 0.88 | MMP1 (0.55) | MMP1MMP13MMP2MMP3MMP7 | |
| SCHEMBL7221683 | 0.87 | MMP1 (0.59) | MMP1MMP13MMP2MMP3MMP7 | |
| SCHEMBL7225630 | 0.87 | MMP1 (0.54) | MMP1MMP13MMP2MMP3MMP7 | |
| SCHEMBL7219971 | 0.87 | MMP1 (0.55) | MMP1MMP13MMP2MMP3MMP7 | |
| SCHEMBL7219120 | 0.85 | MEN1 (0.62) | MMP1MMP13MMP2MMP3MMP7 | |
| SCHEMBL7219592 | 0.85 | MMP1 (0.53) | MMP1MMP13MMP2MMP3MMP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6559142-B2 | Tricyclic substituted cyclic sulfonamides compound is useful for treating heart disease, multiple sclerosis, arthritis, atherosclerosis, and osteoporosis | WARNER-LAMBERT COMPANY | 2003-05-06 | — | — | US | claimed |
| US-20020169160-A1 | Sulfonamide matrix metalloproteinase inhibitors | O'BRIEN PATRICK MICHAEL (US) | 2002-11-14 | — | — | US | claimed |
| EP-1233017-A1 | Tricyclic sulfonamides useful as matrix metalloproteinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2002-08-21 | — | — | EP | claimed |
| US-6559142-B2 | Tricyclic substituted cyclic sulfonamides compound is useful for treating heart disease, multiple sclerosis, arthritis, atherosclerosis, and osteoporosis | WARNER-LAMBERT COMPANY | 2003-05-06 | — | — | US | disclosed |
| US-20020169160-A1 | Sulfonamide matrix metalloproteinase inhibitors | O'BRIEN PATRICK MICHAEL (US) | 2002-11-14 | — | — | US | disclosed |
| EP-1233017-A1 | Tricyclic sulfonamides useful as matrix metalloproteinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2002-08-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020169160-A1 | Sulfonamide matrix metalloproteinase inhibitors | MMP9, MMP10, MMP3 | MMP1 4/4885MMP13 8/4885MMP2 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.